2020年欧洲肿瘤内科学会(ESMO)年会将于9月14日-10月18日在线上召开，其中9月19日-21日的science weekend将有众多肿瘤领域新数据公布。作为欧洲最负盛名及最具影响力的肿瘤学会议，本次会议将展示肿瘤学的最新进展，搭建学术研究与临床实践沟通的桥梁。
作为中国创新药物研发的先行者与领跑者，恒瑞医药多款研发药物再次登录国际舞台，治疗领域涵盖消化道肿瘤、肺癌、骨肉瘤、乳腺癌、头颈部肿瘤、血液肿瘤、妇科肿瘤等多个领域。
今天，先让我们一睹为快，看看有哪些研究即将亮相！
ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced non-squamous non-small-cell lung cancer patients with activating EGFR mutations: a multicentered, randomized,double-blind,placebo-controlled phase IIItrial (CTONG1706)甲磺酸阿帕替尼一线联合吉非替尼治疗晚期EGFR 突变NSCLC 的III期临床研究
1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
卡瑞利珠单抗联合阿帕替尼二线治疗晚期鳞状NSCLC
报告形式：E-Poster
讲者：Guanghui Gao(Shanghai,China)
1366P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
阿帕替尼联合EGFR-TKI治疗EGFR-TKI耐药后的晚期NSCLC(数据更新)讲者：Ruifen Tian(Taiyuan, China)
1804P - The Efficacy of Apatinib plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer阿帕替尼联合拓扑替康作为晚期小细胞肺癌后线治疗疗效 讲者：Haifeng Qin(Beijing, China)
1805P - Apatinib combined with irinotecan in the treatment of small cell lung cancer: a phase 2, single-arm, prospective study
阿帕替尼联合伊立替康治疗小细胞肺癌：II期、单臂、前瞻性研究 讲者：Yanbin Zhao(Harbin, China)
983P-Camrelizumab(C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): an open-label, multi-center, phase 2 trial.卡瑞利珠单抗联合阿帕替尼治疗晚期肝细胞癌(RESCUE)：开放标签、多中心、II期研究讲者：Jianming Xu(Beijing, China)
985P - A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond RECIST-defined progression.卡瑞利珠单抗治疗晚期肝细胞癌的II期研究：RECIST定义进展后持续治疗2 年结果讲者：Zhenggang Ren(Shanghai, China)
81TiP - The changes of immune function and prognosis in advanced perihilar cholangiocarcinoma patients by immunotherapy combined with different topical therapies免疫疗法联合其他类型治疗晚期肝门型胆管细胞癌患者的免疫功能及预后改变讲者：Chao Zhao(Taiyuan,China)
1452P - Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC), the result including the dose level (dl) at 850mg阿帕替尼联合POF( 紫杉醇+FOLFOX) 治疗初治晚期胃癌患者(TNAGC) 的I 期研究，包含850mg 剂量的结果 讲者：Rongbo Lin(Fuzhou, Fujian, China)
1455P - A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer阿帕替尼联合化疗二线治疗晚期胃癌患者的单臂、开放标签、前瞻性、多中心研究讲者：Jifeng Feng(Nanjing, China)
1428P - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study(data updated)阿帕替尼联合多西他赛二线治疗晚期胃癌：前瞻性临床研究(数据更新)讲者：Mudan Yang(Taiyuan, China)
1434P - A prospective, multicenter, nonrandomized,controlled trial of Apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer阿帕替尼联合FLOT方案围手术期化疗及手术治疗III期胃癌的前瞻性多中心非随机对照研究讲者：Jun Zhang(Shenyang, China)
442P - Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer ：One-arm exploratory clinical trial卡瑞利珠单抗联合阿帕替尼治疗晚期胃癌和结直肠癌：单臂探索性临床研究讲者：Li Xiao(Xiamen, China)
1427P - A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction新辅助同步放化疗联合阿帕替尼治疗Siewert II型、Ⅲ型HER2阴性胃食管交界处腺癌的II期临床研究讲者：Qun Zhao(Shijiazhuang, China)
1431P - Study on the safety and efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of nonoperative esophageal cancer阿帕替尼联合同步放化疗治疗不可切除食管癌患者的疗效和安全性讲者：Jingping Yu(Changzhou, China)
1501TiP - The changes of tumor immune microenvironment in esophageal squamous cell carcinoma patients intervened by different neoadjuvant therapies应用不同的新辅助方案治疗食管鳞癌的肿瘤免疫微环境的改变讲者：Wei Li Wang(Taiyuan, China)
1034P - Camrelizumab in the Treatment of Patients with local advanced/metastatic esophageal squamous cell carcinoma (ESCC)：a multi-center, prospective, cohort study卡瑞利珠单抗治疗局部晚期/转移性食管鳞癌(ESCC)：多中心、前瞻性队列研究讲者：Qun Y. Zhu(Su zhou, China)
1503TiP - A Prospective Study of Apatinib in Combination with Neoadjuvant Concurrent Chemoradiotherapy for locally Advanced Esophageal Squamous Cell Carcinoma 阿帕替尼联合同步放化疗新辅助治疗局部晚期食管鳞癌的前瞻性研究讲者：Jun Wang(Shijiazhuang, China)
224P - Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: a single-group, multicenter, phase 2 study 吡咯替尼联合曲妥珠单抗、多西他赛、卡铂新辅助治疗HER2阳性乳腺癌患者：单臂、多中心、II期研究讲者：Zhenzhen Liu(Zhengzhou, China)
225P - Phase 2 study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer吡咯替尼联合白蛋白紫杉醇和曲妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌的II期研究讲者：Ting Luo(Chengdu, Sichuan, China)
294P - Pyrotinib and capecitabine for HER2–Positive metastatic breast cancer patients with previously untreated brain metastases: A single-group multicenter phase II study吡咯替尼联合卡培他滨治疗既往未经治疗脑转移的HER2阳性转移性乳腺癌患者：单臂、多中心、II期研究讲者：Min Yan(Zhengzhou, China)
270P - Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: a multicenter, randomized, phase II,open-label trial阿帕替尼联合紫杉类和铂类用于三阴性和HER2阳性乳腺癌的新辅助治疗：多中心、随机、II期、开放标签研究讲者：Yunjiang J. Liu(Shijiazhuang, China)
15P - Study on the mechanism of apatinib reversing tamoxifen resistance in breast cancer 讲者：Qingxia Li(Shijiazhuang, China)
A Randomized Multicentered Phase 3 Study to Evaluate Apatinib in Subjects with Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer阿帕替尼治疗局部晚期或转移性放射性碘治疗分化型甲状腺癌：多中心随机III期研究
912MO - A single-arm, open-label, multicenter phase 2 study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥ 2 lines of chemotherapy: CAPTAIN study卡瑞利珠单抗治疗接受过2 线及以上化疗后进展的复发/ 转移性鼻咽癌(NPC)患者的单臂、开放标签、多中心、Ⅱ期研究：CAPTAIN讲者：Li Zhang(Guangzhou, China)
941P - Efficacy and Safety of Apatinib Combined with Capecitabine in Patients with Advanced Nasopharyngeal Carcinoma讲者：XiuYu Cai(Guangzhou, China)
893MO - An open-label, single-center,phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma卡瑞利珠单抗联合阿帕替尼治疗复发/ 难治性外周T细胞淋巴瘤的开放标签、单中心、II期、单臂研究 讲者：Yan Xie(Beijing, China)
Efficacy and safety of HHPG-19K for prophylaxis of chemotherapy-induced neutropenia in patients with lymphoma硫培非格司亭用于化疗导致粒细胞减少的淋巴瘤患者的疗效和安全性讲者：Liping Su(Shanxi, China)
840P - Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: an open-label, multicenter phase II study法米替尼联合卡瑞利珠单抗治疗铂类耐药的卵巢/ 输卵管/ 原发性腹膜癌和晚期宫颈癌：开放标签、多中心、II期研究讲者：Lingfang Xia(Shanghai, China)
1646P - Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study讲者：Lu Xie(Beijing, China)
1511P - A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer吡咯替尼治疗HER2 阳性/ 突变肿瘤(乳腺癌除外)的真实世界研究 讲者：Jun Qian(Suzhou, China)
38P - Study on human plasma concentration andserosal permeation of oral apatinib mesylate讲者：Jian Shi(Shijiazhuang, China)注：以上预告内容为ESMO官网截至2020/08/11的最新信息，如需详细内容至ESMO官网查阅。
联众医药网公众号
联众药械圈小程序
联众客服微信号
